Flexible Sigmoidoscopy in the PLCO Cancer Screening Trial: Results From the Baseline Screening Examination of a Randomized Trial
Background: The Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial is a randomized clinical trial to test the effectiveness of cancer screening, including the effect of flexible sigmoidoscopy screening on colorectal cancer mortality. Here we report findings from the baseline screen...
Saved in:
Published in | JNCI : Journal of the National Cancer Institute Vol. 97; no. 13; pp. 989 - 997 |
---|---|
Main Authors | , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Cary, NC
Oxford University Press
06.07.2005
Oxford Publishing Limited (England) |
Subjects | |
Online Access | Get full text |
ISSN | 0027-8874 1460-2105 1460-2105 |
DOI | 10.1093/jnci/dji175 |
Cover
Loading…
Abstract | Background: The Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial is a randomized clinical trial to test the effectiveness of cancer screening, including the effect of flexible sigmoidoscopy screening on colorectal cancer mortality. Here we report findings from the baseline screening flexible sigmoidoscopy examination. Methods: Analyses included 77 465 men and women aged 55–74 years who were enrolled at 10 screening centers. The trial administered baseline risk factor questionnaires, offered 60-cm flexible sigmoidoscopy examinations, referred patients with screen-detected colorectal polyps or masses to personal physicians, and tracked subjects with polyps or masses to determine results from diagnostic follow-up. Cochran–Mantel–Haenszel statistics and logistic regression were used to test for differences in proportions according to sex and age. Results: A total of 64 658 subjects (83.5%) underwent screening flexible sigmoidoscopy, and at least one polyp or mass was identified in 15 150 subjects (23.4%). Of these, 74.2% received follow-up lower endoscopic procedures. Follow-up lower endoscopy was more frequent in subjects with at least one larger (≥0.5 cm) polyp or mass (86.0% [95% confidence interval {CI} = 84.6% to 87.4%] and 81.0% [95% CI = 79.8% to 82.2%] in women and men, respectively) than in those with a smaller (<0.5 cm) polyp or mass (69.1% [95% CI = 67.5% to 70.6%] and 65.4% [95% CI = 64.1% to 66.7%] in women and men, respectively). The yields per 1000 screened, depending on 5-year age group, were as follows: for colorectal cancer, 1.1–2.5 in women and 2.4–5.6 in men; for advanced adenoma, 18.0–30.4 in women and 36.1–49.1 in men; and for colorectal cancer or any adenoma, 50.6–79.6 in women and 101.9–128.6 in men. Approximately 77% (130/169) of the colorectal adenocarcinoma patients were stage I or II at diagnosis. Conclusions: Acceptance of screening flexible sigmoidoscopy was high. Diagnostic follow-up varied according to polyp size, yet cancer or adenoma detection rates met expectations. |
---|---|
AbstractList | The Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial is a randomized clinical trial to test the effectiveness of cancer screening, including the effect of flexible sigmoidoscopy screening on colorectal cancer mortality. Here we report findings from the baseline screening flexible sigmoidoscopy examination.
Analyses included 77,465 men and women aged 55-74 years who were enrolled at 10 screening centers. The trial administered baseline risk factor questionnaires, offered 60-cm flexible sigmoidoscopy examinations, referred patients with screen-detected colorectal polyps or masses to personal physicians, and tracked subjects with polyps or masses to determine results from diagnostic follow-up. Cochran-Mantel-Haenszel statistics and logistic regression were used to test for differences in proportions according to sex and age.
A total of 64 658 subjects (83.5%) underwent screening flexible sigmoidoscopy, and at least one polyp or mass was identified in 15,150 subjects (23.4%). Of these, 74.2% received follow-up lower endoscopic procedures. Follow-up lower endoscopy was more frequent in subjects with at least one larger (> or = 0.5 cm) polyp or mass (86.0% [95% confidence interval {CI} = 84.6% to 87.4%] and 81.0% [95% CI = 79.8% to 82.2%] in women and men, respectively) than in those with a smaller (< 0.5 cm) polyp or mass (69.1% [95% CI = 67.5% to 70.6%] and 65.4% [95% CI = 64.1% to 66.7%] in women and men, respectively). The yields per 1000 screened, depending on 5-year age group, were as follows: for colorectal cancer, 1.1-2.5 in women and 2.4-5.6 in men; for advanced adenoma, 18.0-30.4 in women and 36.1-49.1 in men; and for colorectal cancer or any adenoma, 50.6-79.6 in women and 101.9-128.6 in men. Approximately 77% (130/169) of the colorectal adenocarcinoma patients were stage I or II at diagnosis.
Acceptance of screening flexible sigmoidoscopy was high. Diagnostic follow-up varied according to polyp size, yet cancer or adenoma detection rates met expectations. BACKGROUND: The Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial is a randomized clinical trial to test the effectiveness of cancer screening, including the effect of flexible sigmoidoscopy screening on colorectal cancer mortality. Here we report findings from the baseline screening flexible sigmoidoscopy examination. METHODS: Analyses included 77,465 men and women aged 55-74 years who were enrolled at 10 screening centers. The trial administered baseline risk factor questionnaires, offered 60-cm flexible sigmoidoscopy examinations, referred patients with screen-detected colorectal polyps or masses to personal physicians, and tracked subjects with polyps or masses to determine results from diagnostic follow-up. Cochran-Mantel-Haenszel statistics and logistic regression were used to test for differences in proportions according to sex and age. RESULTS: A total of 64 658 subjects (83.5%) underwent screening flexible sigmoidoscopy, and at least one polyp or mass was identified in 15,150 subjects (23.4%). Of these, 74.2% received follow-up lower endoscopic procedures. Follow-up lower endoscopy was more frequent in subjects with at least one larger (> or = 0.5 cm) polyp or mass (86.0% [95% confidence interval {CI} = 84.6% to 87.4%] and 81.0% [95% CI = 79.8% to 82.2%] in women and men, respectively) than in those with a smaller (< 0.5 cm) polyp or mass (69.1% [95% CI = 67.5% to 70.6%] and 65.4% [95% CI = 64.1% to 66.7%] in women and men, respectively). The yields per 1000 screened, depending on 5-year age group, were as follows: for colorectal cancer, 1.1-2.5 in women and 2.4-5.6 in men; for advanced adenoma, 18.0-30.4 in women and 36.1-49.1 in men; and for colorectal cancer or any adenoma, 50.6-79.6 in women and 101.9-128.6 in men. Approximately 77% (130/169) of the colorectal adenocarcinoma patients were stage I or II at diagnosis. CONCLUSIONS: Acceptance of screening flexible sigmoidoscopy was high. Diagnostic follow-up varied according to polyp size, yet cancer or adenoma detection rates met expectations. The Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial is a randomized clinical trial to test the effectiveness of cancer screening, including the effect of flexible sigmoidoscopy screening on colorectal cancer mortality. Here we report findings from the baseline screening flexible sigmoidoscopy examination.BACKGROUNDThe Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial is a randomized clinical trial to test the effectiveness of cancer screening, including the effect of flexible sigmoidoscopy screening on colorectal cancer mortality. Here we report findings from the baseline screening flexible sigmoidoscopy examination.Analyses included 77,465 men and women aged 55-74 years who were enrolled at 10 screening centers. The trial administered baseline risk factor questionnaires, offered 60-cm flexible sigmoidoscopy examinations, referred patients with screen-detected colorectal polyps or masses to personal physicians, and tracked subjects with polyps or masses to determine results from diagnostic follow-up. Cochran-Mantel-Haenszel statistics and logistic regression were used to test for differences in proportions according to sex and age.METHODSAnalyses included 77,465 men and women aged 55-74 years who were enrolled at 10 screening centers. The trial administered baseline risk factor questionnaires, offered 60-cm flexible sigmoidoscopy examinations, referred patients with screen-detected colorectal polyps or masses to personal physicians, and tracked subjects with polyps or masses to determine results from diagnostic follow-up. Cochran-Mantel-Haenszel statistics and logistic regression were used to test for differences in proportions according to sex and age.A total of 64 658 subjects (83.5%) underwent screening flexible sigmoidoscopy, and at least one polyp or mass was identified in 15,150 subjects (23.4%). Of these, 74.2% received follow-up lower endoscopic procedures. Follow-up lower endoscopy was more frequent in subjects with at least one larger (> or = 0.5 cm) polyp or mass (86.0% [95% confidence interval {CI} = 84.6% to 87.4%] and 81.0% [95% CI = 79.8% to 82.2%] in women and men, respectively) than in those with a smaller (< 0.5 cm) polyp or mass (69.1% [95% CI = 67.5% to 70.6%] and 65.4% [95% CI = 64.1% to 66.7%] in women and men, respectively). The yields per 1000 screened, depending on 5-year age group, were as follows: for colorectal cancer, 1.1-2.5 in women and 2.4-5.6 in men; for advanced adenoma, 18.0-30.4 in women and 36.1-49.1 in men; and for colorectal cancer or any adenoma, 50.6-79.6 in women and 101.9-128.6 in men. Approximately 77% (130/169) of the colorectal adenocarcinoma patients were stage I or II at diagnosis.RESULTSA total of 64 658 subjects (83.5%) underwent screening flexible sigmoidoscopy, and at least one polyp or mass was identified in 15,150 subjects (23.4%). Of these, 74.2% received follow-up lower endoscopic procedures. Follow-up lower endoscopy was more frequent in subjects with at least one larger (> or = 0.5 cm) polyp or mass (86.0% [95% confidence interval {CI} = 84.6% to 87.4%] and 81.0% [95% CI = 79.8% to 82.2%] in women and men, respectively) than in those with a smaller (< 0.5 cm) polyp or mass (69.1% [95% CI = 67.5% to 70.6%] and 65.4% [95% CI = 64.1% to 66.7%] in women and men, respectively). The yields per 1000 screened, depending on 5-year age group, were as follows: for colorectal cancer, 1.1-2.5 in women and 2.4-5.6 in men; for advanced adenoma, 18.0-30.4 in women and 36.1-49.1 in men; and for colorectal cancer or any adenoma, 50.6-79.6 in women and 101.9-128.6 in men. Approximately 77% (130/169) of the colorectal adenocarcinoma patients were stage I or II at diagnosis.Acceptance of screening flexible sigmoidoscopy was high. Diagnostic follow-up varied according to polyp size, yet cancer or adenoma detection rates met expectations.CONCLUSIONSAcceptance of screening flexible sigmoidoscopy was high. Diagnostic follow-up varied according to polyp size, yet cancer or adenoma detection rates met expectations. Background: The Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial is a randomized clinical trial to test the effectiveness of cancer screening, including the effect of flexible sigmoidoscopy screening on colorectal cancer mortality. Here we report findings from the baseline screening flexible sigmoidoscopy examination. Methods: Analyses included 77 465 men and women aged 55–74 years who were enrolled at 10 screening centers. The trial administered baseline risk factor questionnaires, offered 60-cm flexible sigmoidoscopy examinations, referred patients with screen-detected colorectal polyps or masses to personal physicians, and tracked subjects with polyps or masses to determine results from diagnostic follow-up. Cochran–Mantel–Haenszel statistics and logistic regression were used to test for differences in proportions according to sex and age. Results: A total of 64 658 subjects (83.5%) underwent screening flexible sigmoidoscopy, and at least one polyp or mass was identified in 15 150 subjects (23.4%). Of these, 74.2% received follow-up lower endoscopic procedures. Follow-up lower endoscopy was more frequent in subjects with at least one larger (≥0.5 cm) polyp or mass (86.0% [95% confidence interval {CI} = 84.6% to 87.4%] and 81.0% [95% CI = 79.8% to 82.2%] in women and men, respectively) than in those with a smaller (<0.5 cm) polyp or mass (69.1% [95% CI = 67.5% to 70.6%] and 65.4% [95% CI = 64.1% to 66.7%] in women and men, respectively). The yields per 1000 screened, depending on 5-year age group, were as follows: for colorectal cancer, 1.1–2.5 in women and 2.4–5.6 in men; for advanced adenoma, 18.0–30.4 in women and 36.1–49.1 in men; and for colorectal cancer or any adenoma, 50.6–79.6 in women and 101.9–128.6 in men. Approximately 77% (130/169) of the colorectal adenocarcinoma patients were stage I or II at diagnosis. Conclusions: Acceptance of screening flexible sigmoidoscopy was high. Diagnostic follow-up varied according to polyp size, yet cancer or adenoma detection rates met expectations. |
Author | Schoen, Robert E. Pinsky, Paul F. Church, Timothy Gohagan, John K. Weissfeld, Joel L. Bresalier, Robert S. Prorok, Philip C. Yurgalevitch, Susan Austin, Joseph H. |
Author_xml | – sequence: 1 givenname: Joel L. surname: Weissfeld fullname: Weissfeld, Joel L. organization: University of Pittsburgh Cancer Institute, Pittsburgh, PA (JLW, RES); Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, MD (PFP, PCP, JKG); Henry Ford Hospital, Detroit, MI (RSB); University of Minnesota, Minneapolis, MN (TC); Westat, Rockville, MD (SY); Information Management Services, Inc., Rockville, MD (JHA) – sequence: 2 givenname: Robert E. surname: Schoen fullname: Schoen, Robert E. organization: University of Pittsburgh Cancer Institute, Pittsburgh, PA (JLW, RES); Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, MD (PFP, PCP, JKG); Henry Ford Hospital, Detroit, MI (RSB); University of Minnesota, Minneapolis, MN (TC); Westat, Rockville, MD (SY); Information Management Services, Inc., Rockville, MD (JHA) – sequence: 3 givenname: Paul F. surname: Pinsky fullname: Pinsky, Paul F. organization: University of Pittsburgh Cancer Institute, Pittsburgh, PA (JLW, RES); Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, MD (PFP, PCP, JKG); Henry Ford Hospital, Detroit, MI (RSB); University of Minnesota, Minneapolis, MN (TC); Westat, Rockville, MD (SY); Information Management Services, Inc., Rockville, MD (JHA) – sequence: 4 givenname: Robert S. surname: Bresalier fullname: Bresalier, Robert S. organization: University of Pittsburgh Cancer Institute, Pittsburgh, PA (JLW, RES); Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, MD (PFP, PCP, JKG); Henry Ford Hospital, Detroit, MI (RSB); University of Minnesota, Minneapolis, MN (TC); Westat, Rockville, MD (SY); Information Management Services, Inc., Rockville, MD (JHA) – sequence: 5 givenname: Timothy surname: Church fullname: Church, Timothy organization: University of Pittsburgh Cancer Institute, Pittsburgh, PA (JLW, RES); Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, MD (PFP, PCP, JKG); Henry Ford Hospital, Detroit, MI (RSB); University of Minnesota, Minneapolis, MN (TC); Westat, Rockville, MD (SY); Information Management Services, Inc., Rockville, MD (JHA) – sequence: 6 givenname: Susan surname: Yurgalevitch fullname: Yurgalevitch, Susan organization: University of Pittsburgh Cancer Institute, Pittsburgh, PA (JLW, RES); Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, MD (PFP, PCP, JKG); Henry Ford Hospital, Detroit, MI (RSB); University of Minnesota, Minneapolis, MN (TC); Westat, Rockville, MD (SY); Information Management Services, Inc., Rockville, MD (JHA) – sequence: 7 givenname: Joseph H. surname: Austin fullname: Austin, Joseph H. organization: University of Pittsburgh Cancer Institute, Pittsburgh, PA (JLW, RES); Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, MD (PFP, PCP, JKG); Henry Ford Hospital, Detroit, MI (RSB); University of Minnesota, Minneapolis, MN (TC); Westat, Rockville, MD (SY); Information Management Services, Inc., Rockville, MD (JHA) – sequence: 8 givenname: Philip C. surname: Prorok fullname: Prorok, Philip C. organization: University of Pittsburgh Cancer Institute, Pittsburgh, PA (JLW, RES); Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, MD (PFP, PCP, JKG); Henry Ford Hospital, Detroit, MI (RSB); University of Minnesota, Minneapolis, MN (TC); Westat, Rockville, MD (SY); Information Management Services, Inc., Rockville, MD (JHA) – sequence: 9 givenname: John K. surname: Gohagan fullname: Gohagan, John K. organization: University of Pittsburgh Cancer Institute, Pittsburgh, PA (JLW, RES); Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, MD (PFP, PCP, JKG); Henry Ford Hospital, Detroit, MI (RSB); University of Minnesota, Minneapolis, MN (TC); Westat, Rockville, MD (SY); Information Management Services, Inc., Rockville, MD (JHA) |
BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=16945605$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/15998952$$D View this record in MEDLINE/PubMed |
BookMark | eNpt0c9v0zAUB3ALDbFucOKOLCR2mcJsJ3aS3aBaO6RKm9rxQ1wsx3kZLo5d7ETqOPGnky5loAlffPm8r57e9wgdOO8AoZeUvKWkTM_WTpuzem1ozp-gCc0ESRgl_ABNCGF5UhR5doiOYlyT4ZUse4YOKS_LouRsgn7NLGxNZQGvzG3rTe2j9ps7bBzuvgG-Xkyv8FQ5DQGvdABwxt3im2CUPcdLiL3tIp4F397r9yqCNQ7-oRdb1RqnOuMd9g1WeKlc7VvzE-ox5jl62igb4cX-P0YfZxc308tkcTX_MH23SHRW8C4pVZM3VV0oClVapUCoBg6ZZiLLC51XjBYpaQgTJKOVUgwykVWaF0o3omKMp8foZMzdBP-jh9jJ1kQN1ioHvo9SFISynJcDfP0Irn0f3LCbZIyUJaEpHdCrPeqrFmq5CaZV4U7-OewA3uyBilrZJgw3NPGvE2XGBdmtRUeng48xQCO16e7P1QVlrKRE7kqWu5LlWPIwc_po5iH2vzoZtYkdbB-oCt-lyNOcy8svX6W4zj9_ms9Xcpn-BqYZuT8 |
CODEN | JNCIEQ |
CitedBy_id | crossref_primary_10_1111_bju_13154 crossref_primary_10_1080_00365521_2024_2364213 crossref_primary_10_1016_S0140_6736_10_60551_X crossref_primary_10_1016_j_gtc_2007_12_015 crossref_primary_10_1186_1741_7015_9_133 crossref_primary_10_1016_j_canep_2011_10_013 crossref_primary_10_1111_j_1463_1318_2008_01548_x crossref_primary_10_3389_fnut_2023_1167372 crossref_primary_10_1016_j_bpg_2014_03_002 crossref_primary_10_1177_0969141313501292 crossref_primary_10_1053_j_gastro_2018_07_017 crossref_primary_10_1016_j_cgh_2012_08_002 crossref_primary_10_1017_S1368980017000453 crossref_primary_10_1016_j_cgh_2009_01_016 crossref_primary_10_1007_s10620_012_2146_z crossref_primary_10_1258_jms_2010_010055 crossref_primary_10_1038_nrgastro_2010_111 crossref_primary_10_1002_cncr_25048 crossref_primary_10_1016_j_urolonc_2014_06_009 crossref_primary_10_1177_0969141319879955 crossref_primary_10_1007_s10350_007_9123_1 crossref_primary_10_1111_j_1365_2753_2012_01845_x crossref_primary_10_1136_gutjnl_2014_308002 crossref_primary_10_1186_s12967_023_04352_8 crossref_primary_10_1371_journal_pone_0220234 crossref_primary_10_1371_journal_pmed_1001352 crossref_primary_10_1093_ajcn_86_5_1754 crossref_primary_10_1093_pubmed_fdp115 crossref_primary_10_1111_j_1572_0241_2006_00433_x crossref_primary_10_1016_j_juro_2014_05_087 crossref_primary_10_1053_j_gastro_2009_09_062 crossref_primary_10_1111_jgh_13634 crossref_primary_10_1007_s00384_019_03425_9 crossref_primary_10_1093_jnci_djm065 crossref_primary_10_1053_j_gastro_2020_11_037 crossref_primary_10_1002_ijc_23273 crossref_primary_10_1093_glycob_cwad035 crossref_primary_10_1007_s11888_011_0108_z crossref_primary_10_1016_j_soncn_2013_12_010 crossref_primary_10_1007_BF03087670 crossref_primary_10_1016_S1507_1367_10_60057_0 crossref_primary_10_1038_ajg_2010_349 crossref_primary_10_1016_j_canep_2014_12_011 crossref_primary_10_1016_S0210_5705_12_70036_5 crossref_primary_10_5694_j_1326_5377_2007_tb01241_x crossref_primary_10_1016_j_gie_2007_08_048 crossref_primary_10_1016_j_gie_2012_06_013 crossref_primary_10_1093_clinchem_hvad198 crossref_primary_10_1007_s00384_023_04524_4 crossref_primary_10_1016_j_gie_2006_06_037 crossref_primary_10_1016_j_juro_2009_02_142 crossref_primary_10_1002_ijc_28457 crossref_primary_10_1016_j_ypmed_2018_12_004 crossref_primary_10_1136_bmjopen_2019_032773 crossref_primary_10_1177_548_6506 crossref_primary_10_1177_1758834011419550 crossref_primary_10_1016_j_bpg_2016_04_006 crossref_primary_10_1002_ijc_24371 crossref_primary_10_1038_sj_bjc_6602806 crossref_primary_10_1186_1748_5908_7_51 crossref_primary_10_1016_j_gcb_2009_07_014 crossref_primary_10_1111_j_1572_0241_2006_00756_1_x crossref_primary_10_4137_CGast_S14039 crossref_primary_10_1016_S0140_6736_10_60353_4 crossref_primary_10_1136_gutjnl_2014_309086 crossref_primary_10_1200_JCO_2011_40_1943 crossref_primary_10_2214_AJR_07_2899 crossref_primary_10_1016_j_gie_2015_06_049 crossref_primary_10_1016_j_gie_2011_10_024 crossref_primary_10_1001_jama_2021_5746 crossref_primary_10_1016_S0210_5705_13_70055_4 crossref_primary_10_1093_jnci_djr549 crossref_primary_10_1001_jama_2021_4417 crossref_primary_10_1136_bmjopen_2015_008254 crossref_primary_10_1016_S0210_5705_08_75814_X crossref_primary_10_1111_j_1572_0241_2008_01932_x crossref_primary_10_1158_1055_9965_EPI_06_0460 crossref_primary_10_1016_j_cgh_2019_12_031 crossref_primary_10_1586_egh_10_65 crossref_primary_10_1093_jncics_pkac027 crossref_primary_10_1016_j_bpg_2010_06_005 crossref_primary_10_1016_j_pop_2007_02_002 crossref_primary_10_1038_bjc_2013_434 crossref_primary_10_1016_j_bpg_2010_06_004 crossref_primary_10_1002_14651858_CD001216_pub2 crossref_primary_10_1158_1055_9965_EPI_06_0747 crossref_primary_10_1111_codi_12377 crossref_primary_10_2217_crc_12_33 crossref_primary_10_14309_ctg_0000000000000782 crossref_primary_10_1186_1745_6215_14_40 crossref_primary_10_1056_NEJMoa1114635 crossref_primary_10_1111_j_1365_2796_2011_02399_x crossref_primary_10_1007_s11606_011_1919_y crossref_primary_10_1053_j_gastro_2007_03_030 crossref_primary_10_1093_jnci_djq068 crossref_primary_10_1053_j_gastro_2008_02_002 crossref_primary_10_1118_1_2830376 crossref_primary_10_1053_j_gastro_2006_08_025 crossref_primary_10_1186_s12889_023_16564_0 crossref_primary_10_2217_iim_10_9 crossref_primary_10_1016_j_cgh_2008_07_014 crossref_primary_10_1148_radiol_11101702 crossref_primary_10_1093_jnci_djr284 crossref_primary_10_7326_M23_0779 crossref_primary_10_1016_S0210_5705_11_70022_X crossref_primary_10_1016_j_gcb_2009_07_008 crossref_primary_10_1093_ajcn_86_6_1754 crossref_primary_10_1093_carcin_bgr071 crossref_primary_10_1038_srep20396 |
Cites_doi | 10.1002/bjs.1800840922 10.1016/S0016-5085(08)80325-3 10.1093/jnci/94.23.1763 10.1007/BF02563693 10.1016/S0140-6736(96)03430-7 10.1053/gast.1999.0029900312 10.1016/S0140-6736(96)03386-7 10.1016/S0140-6736(02)08268-5 10.1007/BF00642439 10.1001/jama.290.1.41a 10.1136/gut.50.1.29 10.7326/0003-4819-139-12-200312160-00005 10.1136/bmj.317.7152.182 10.1001/jama.281.17.1611 10.1001/archinte.160.12.1790 10.1016/S0016-5085(97)70214-2 10.1080/00365520310006513 10.1053/j.gastro.2004.01.023 10.1056/NEJM200011303432203 10.1007/s003840050108 10.1007/BF02604312 10.1080/00365520310003002 10.1016/S0197-2456(00)00096-9 10.1136/gut.42.4.560 10.1093/jnci/91.5.434 |
ContentType | Journal Article |
Copyright | 2005 INIST-CNRS Copyright Oxford University Press(England) Jul 6, 2005 |
Copyright_xml | – notice: 2005 INIST-CNRS – notice: Copyright Oxford University Press(England) Jul 6, 2005 |
CorporateAuthor | PLCO Project Team |
CorporateAuthor_xml | – name: PLCO Project Team |
DBID | BSCLL AAYXX CITATION IQODW CGR CUY CVF ECM EIF NPM 7TO 7U7 7U9 C1K H94 K9. NAPCQ 7X8 |
DOI | 10.1093/jnci/dji175 |
DatabaseName | Istex CrossRef Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Oncogenes and Growth Factors Abstracts Toxicology Abstracts Virology and AIDS Abstracts Environmental Sciences and Pollution Management AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Premium MEDLINE - Academic |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Nursing & Allied Health Premium Virology and AIDS Abstracts Oncogenes and Growth Factors Abstracts Toxicology Abstracts AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Environmental Sciences and Pollution Management MEDLINE - Academic |
DatabaseTitleList | MEDLINE Nursing & Allied Health Premium MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1460-2105 |
EndPage | 997 |
ExternalDocumentID | 948585841 15998952 16945605 10_1093_jnci_dji175 ark_67375_HXZ_6P7WVGGS_R |
Genre | Research Support, U.S. Gov't, P.H.S Clinical Trial Randomized Controlled Trial Journal Article Research Support, N.I.H., Extramural |
GeographicLocations | United States North America America |
GeographicLocations_xml | – name: United States |
GroupedDBID | --- -E4 -~X .2P .55 .GJ .I3 .XZ .ZR 08P 0R~ 1TH 29L 2WC 354 3O- 4.4 482 48X 53G 5GY 5RE 5VS 5WD 70D 96U AABZA AACZT AAHTB AAJKP AAJQQ AAKAS AAMVS AAOGV AAPNW AAPQZ AAPXW AARHZ AAUAY AAUQX AAVAP AAWTL ABCQX ABDFA ABEFU ABEJV ABEUO ABGNP ABIXL ABJNI ABKDP ABNGD ABNHQ ABNKS ABOCM ABPEJ ABPMR ABPPZ ABPTD ABQLI ABQNK ABVGC ABXVV ABZBJ ACBMB ACGFO ACGFS ACGOD ACKOT ACNCT ACPRK ACUFI ACUKT ACUTO ACYHN ADBBV ADEYI ADEZT ADGZP ADHKW ADHZD ADIPN ADNBA ADOCK ADQBN ADRTK ADVEK ADXHL ADYVW ADZCM AEGPL AEJOX AEKSI AEMDU AEMQT AENZO AEPUE AETBJ AEWNT AFAZI AFCHL AFFNX AFFZL AFIYH AFOFC AFRAH AFXAL AFYAG AGINJ AGKEF AGORE AGQPQ AGSYK AGUTN AHMBA AHMMS AHXPO AIAGR AIJHB AJBYB AJEEA AJNCP ALMA_UNASSIGNED_HOLDINGS ALUQC ALXQX APIBT APWMN ASPBG ATGXG AVWKF AZFZN BAWUL BAYMD BCRHZ BEYMZ BKOMP BSCLL BTRTY BVRKM C45 CAG CDBKE COF CS3 CZ4 DAKXR DIK DILTD DU5 D~K E3Z EBS EE~ EJD EMOBN ENERS F5P F8P F9B FECEO FEDTE FLUFQ FOEOM FOTVD FQBLK GAUVT GJXCC GX1 H5~ HAR HVGLF HW0 HZ~ IH2 IOX J21 J5H JXSIZ KAQDR KBUDW KOP KQ8 KSI KSN L7B M-Z MHKGH ML0 N9A NGC NOMLY NOYVH NTWIH NVLIB O0~ OAUYM OAWHX OBH OCB OCZFY ODMLO ODZKP OGEVE OHH OJQWA OJZSN OK1 OPAEJ OVD OWPYF P2P PAFKI PB- PEELM PQQKQ Q.- Q1. Q5Y R44 RD5 RNS ROL ROX ROZ RUSNO RW1 RXO TCURE TEORI TJX TMA TR2 TWZ UDS UPT VVN W8F WH7 WOQ X7H X7M YAYTL YHZ YKOAZ YQT YXANX ZKX ZRR ZY1 ~91 ~H1 AAYXX CITATION -DD 186 2QL 8WZ A6W AAGKA AAPGJ AAQQT AAWDT ABSMQ ACFRR ACPQN ACUTJ ACVCV ACZBC ADMTO AEHUL AEKPW AETEA AFFQV AFSHK AGKRT AGMDO AGNAY AHGBF AI. AJDVS APJGH AQDSO AQKUS ATTQO AVNTJ BZKNY EIHJH FA8 GOZPB GRPMH H13 IQODW LXL LXN LXY MBLQV MVM NU- OBFPC O~Y QBD RNI RZF RZO VH1 XJT Y6R YR5 ~X8 ABQTQ ADJQC ADRIX ADZXQ CGR CUY CVF ECM EIF NPM RHF VXZ 7TO 7U7 7U9 C1K H94 K9. NAPCQ 7X8 |
ID | FETCH-LOGICAL-c485t-9af7fbd8a1eb3b3e01ce5e4c26478c7b21830f026041baa2e464bc58acf6b2253 |
ISSN | 0027-8874 1460-2105 |
IngestDate | Fri Jul 11 04:01:38 EDT 2025 Mon Jun 30 08:41:40 EDT 2025 Wed Feb 19 01:52:00 EST 2025 Mon Jul 21 09:14:42 EDT 2025 Tue Jul 01 03:24:29 EDT 2025 Thu Apr 24 22:55:38 EDT 2025 Tue Aug 05 16:48:45 EDT 2025 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 13 |
Keywords | Human Rectal disease Sigmoidoscopy Colorectal cancer Malignant tumor Medical screening Colonic disease Colorectal adenoma Cancerology Flexible Digestive diseases Intestinal disease Clinical trial Endoscopy Benign neoplasm Colon Public health |
Language | English |
License | CC BY 4.0 |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c485t-9af7fbd8a1eb3b3e01ce5e4c26478c7b21830f026041baa2e464bc58acf6b2253 |
Notes | local:dji175 istex:0CE72B04912EF6C05B7FC5F7E158B16204DB752A Correspondence to: Joel L. Weissfeld, MD, MPH, UPMC Cancer Pavilion (POB II), 3rd Floor Centre Medical Building, 5150 Centre Avenue, Pittsburgh, PA 15232 (e-mail: jwepid@pitt.edu). ark:/67375/HXZ-6P7WVGGS-R ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 14 content type line 23 ObjectType-Undefined-3 |
OpenAccessLink | https://academic.oup.com/jnci/article-pdf/97/13/989/7686234/dji175.pdf |
PMID | 15998952 |
PQID | 220990131 |
PQPubID | 41605 |
PageCount | 9 |
ParticipantIDs | proquest_miscellaneous_68012759 proquest_journals_220990131 pubmed_primary_15998952 pascalfrancis_primary_16945605 crossref_citationtrail_10_1093_jnci_dji175 crossref_primary_10_1093_jnci_dji175 istex_primary_ark_67375_HXZ_6P7WVGGS_R |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2005-07-06 |
PublicationDateYYYYMMDD | 2005-07-06 |
PublicationDate_xml | – month: 07 year: 2005 text: 2005-07-06 day: 06 |
PublicationDecade | 2000 |
PublicationPlace | Cary, NC |
PublicationPlace_xml | – name: Cary, NC – name: United States – name: Oxford |
PublicationTitle | JNCI : Journal of the National Cancer Institute |
PublicationTitleAlternate | JNCI J Natl Cancer Inst |
PublicationYear | 2005 |
Publisher | Oxford University Press Oxford Publishing Limited (England) |
Publisher_xml | – name: Oxford University Press – name: Oxford Publishing Limited (England) |
References | key 20171012213256_BIB30 key 20171012213256_BIB10 key 20171012213256_BIB1 key 20171012213256_BIB23 key 20171012213256_BIB22 key 20171012213256_BIB3 key 20171012213256_BIB25 key 20171012213256_BIB2 key 20171012213256_BIB24 key 20171012213256_BIB5 key 20171012213256_BIB27 key 20171012213256_BIB4 key 20171012213256_BIB26 key 20171012213256_BIB7 key 20171012213256_BIB29 key 20171012213256_BIB6 key 20171012213256_BIB28 key 20171012213256_BIB9 key 20171012213256_BIB8 key 20171012213256_BIB21 key 20171012213256_BIB20 key 20171012213256_BIB12 key 20171012213256_BIB11 key 20171012213256_BIB14 key 20171012213256_BIB13 key 20171012213256_BIB16 key 20171012213256_BIB15 key 20171012213256_BIB18 key 20171012213256_BIB17 key 20171012213256_BIB19 |
References_xml | – ident: key 20171012213256_BIB15 doi: 10.1002/bjs.1800840922 – ident: key 20171012213256_BIB10 – ident: key 20171012213256_BIB16 – ident: key 20171012213256_BIB26 doi: 10.1016/S0016-5085(08)80325-3 – ident: key 20171012213256_BIB8 doi: 10.1093/jnci/94.23.1763 – ident: key 20171012213256_BIB24 doi: 10.1007/BF02563693 – ident: key 20171012213256_BIB3 doi: 10.1016/S0140-6736(96)03430-7 – ident: key 20171012213256_BIB29 doi: 10.1053/gast.1999.0029900312 – ident: key 20171012213256_BIB4 doi: 10.1016/S0140-6736(96)03386-7 – ident: key 20171012213256_BIB7 doi: 10.1016/S0140-6736(02)08268-5 – ident: key 20171012213256_BIB21 doi: 10.1007/BF00642439 – ident: key 20171012213256_BIB18 doi: 10.1001/jama.290.1.41a – ident: key 20171012213256_BIB5 doi: 10.1136/gut.50.1.29 – ident: key 20171012213256_BIB11 doi: 10.7326/0003-4819-139-12-200312160-00005 – ident: key 20171012213256_BIB14 doi: 10.1136/bmj.317.7152.182 – ident: key 20171012213256_BIB23 doi: 10.1001/jama.281.17.1611 – ident: key 20171012213256_BIB13 – ident: key 20171012213256_BIB17 doi: 10.1001/archinte.160.12.1790 – ident: key 20171012213256_BIB30 doi: 10.1016/S0016-5085(97)70214-2 – ident: key 20171012213256_BIB28 doi: 10.1080/00365520310006513 – ident: key 20171012213256_BIB27 doi: 10.1053/j.gastro.2004.01.023 – ident: key 20171012213256_BIB1 doi: 10.1056/NEJM200011303432203 – ident: key 20171012213256_BIB22 doi: 10.1007/s003840050108 – ident: key 20171012213256_BIB25 doi: 10.1007/BF02604312 – ident: key 20171012213256_BIB9 doi: 10.1080/00365520310003002 – ident: key 20171012213256_BIB20 – ident: key 20171012213256_BIB6 doi: 10.1016/S0197-2456(00)00096-9 – ident: key 20171012213256_BIB19 – ident: key 20171012213256_BIB12 doi: 10.1136/gut.42.4.560 – ident: key 20171012213256_BIB2 doi: 10.1093/jnci/91.5.434 |
SSID | ssj0000924 |
Score | 2.246819 |
Snippet | Background: The Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial is a randomized clinical trial to test the effectiveness of cancer... The Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial is a randomized clinical trial to test the effectiveness of cancer screening,... BACKGROUND: The Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial is a randomized clinical trial to test the effectiveness of cancer... |
SourceID | proquest pubmed pascalfrancis crossref istex |
SourceType | Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 989 |
SubjectTerms | Adenoma - diagnosis Adenoma - mortality Age Distribution Aged Biological and medical sciences Carcinoma - diagnosis Carcinoma - mortality Clinical trials Colonic Polyps - diagnosis Colonic Polyps - mortality Colorectal cancer Colorectal Neoplasms - diagnosis Colorectal Neoplasms - mortality Colorectal Neoplasms - prevention & control Diagnostic tests Digestive system. Abdomen Endoscopy Female Humans Investigative techniques, diagnostic techniques (general aspects) Male Mass Screening - methods Medical sciences Medical screening Middle Aged Mortality Sex Distribution Sigmoidoscopy Surveys and Questionnaires Tumors United States - epidemiology |
Title | Flexible Sigmoidoscopy in the PLCO Cancer Screening Trial: Results From the Baseline Screening Examination of a Randomized Trial |
URI | https://api.istex.fr/ark:/67375/HXZ-6P7WVGGS-R/fulltext.pdf https://www.ncbi.nlm.nih.gov/pubmed/15998952 https://www.proquest.com/docview/220990131 https://www.proquest.com/docview/68012759 |
Volume | 97 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3db9MwELeqTUK8IL4pg-GHiQembvlOwxur2pWp66qthYqXyE7sqWNLUT-kbU_8xfwN3NnOlxgIUKWoSqxzkvvFPp9_d0fIThAIl8lItDiG_3oebhIix90O21ImkSMDVXnueBj0J97R1J82Gj8qrKX1iu8lt3fGlfyPVuEc6BWjZP9Bs4VQOAH_Qb9wBA3D8a903MNslhj6dDY7v5rP0jnGmNzk1MXRoHOy20GtLuATRn4NugXGeF-aBrdcX66WYLqaAJMDpoLTRaVx95ohVSa3KtnuKcvS-dXsFsxUJahm2w47H5WHoWLkKgpl7m8091LwE8pdIdC-NKWyj5BrW3ikMUmoHhg1BbwMnBhhye2bnNxYEpQPFmIJawtR4Y0b927u2_AVDzYoV8I6ZrLikDNRX2h9myInucMkj02AObet6_7sCT2ke4HVgoWtXx3zNSc4x7ZbGcEjXdHol5lFZ926yBJERXoxs3XBl3oG7-FJ3JsMBvG4Ox3XryqLATPxwA_zLGw6sKxRpUamJSXJihyTNVw_hYknha73seN93W3NgtrEweAaGb1sCR-11NVYfr9cUmbT-CF5YKBAP2jwPiINkT0m944No-MJ-Z5jmNYwTGcZBexQxDDVuKEFLKmC3ntqEEwRwap1juBK0wqC6VxSRksEazFPyaTXHXf6LVMVpJXA61u1IiZDydM2swV3uSssOxG-8BIHo6aTkKPNb0lMlefZnDFHeIHHE7_NEhlwmL3cZ2Qjm2fiBaFpmwsW-QEPE-nJ1Iu8FMzzBAuvc8dKeZO8y990nJiU-Vi55TLW1A03RrXEWi1NslM0_qYzxdzd7K1SWdGGLb4iuTL04_70SxyMws-fDg_P4tMm2a7ptBQaRLDqsUDSVq7k2AxKy9hx1E63azfJm-IqzBi4DcgyMV8v4wCN0tCPmuS5RkYp2Y8A_r7z8o-St8j98lt9RTZWi7V4DZb5im8rOP8EqDvpiQ |
linkProvider | Geneva Foundation for Medical Education and Research |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Flexible+Sigmoidoscopy+in+the+PLCO+Cancer+Screening+Trial%3A+Results+From+the+Baseline+Screening+Examination+of+a+Randomized+Trial&rft.jtitle=JNCI+%3A+Journal+of+the+National+Cancer+Institute&rft.au=Weissfeld%2C+Joel+L&rft.au=Schoen%2C+Robert+E&rft.au=Pinsky%2C+Paul+F&rft.au=Bresalier%2C+Robert+S&rft.date=2005-07-06&rft.pub=Oxford+Publishing+Limited+%28England%29&rft.issn=0027-8874&rft.eissn=1460-2105&rft.volume=97&rft.issue=13&rft.spage=989&rft_id=info:doi/10.1093%2Fjnci%2Fdji175&rft.externalDBID=NO_FULL_TEXT&rft.externalDocID=948585841 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0027-8874&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0027-8874&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0027-8874&client=summon |